Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | Iambic will train its AI models with Revolution’s collection of proprietary data to pinpoint potential new oncology targets. The deal could yield the AI discovery outfit up to $25 million in upfront and milestone-based payments.